Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965011 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9845285 | 0.80 | PIK3CG (0.33) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9124435 | 0.79 | — | — | |
| SCHEMBL9019861 | 0.78 | ALDH1A1 (0.34) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9019773 | 0.76 | PDE3A (0.39) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL8960765 | 0.76 | ELANE (0.32) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9845287 | 0.75 | KDM4E (0.31) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9019744 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL9019755 | 0.73 | ALDH1A1 (0.32) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| SCHEMBL8210030 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| US-20250339502-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20230147602-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021188866-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188974-A1 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | ORGENESIS INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
| EP-2842559-A2 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | Chimerix, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
| EP-1868628-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-1865967-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | Chimerix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007047339-A2 | METHODS OF INHIBITING POXVIRUS GROWTH | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006110656-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX INC (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | CHIMERIX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| WO-2006110656-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110655-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1077454-A | 2-amino-7- [ (1, 3-dihydroxy-2-propoxy) methyl ] purine carboxylate, its preparation and use | HOECHST AG (DE) | 1993-10-20 | — | — | CN | disclosed |
| US-5225550-A | PROCESS FOR THE PREPARATION OF SUBSTITUTED ACYCLIC NUCLEOSIDES, AND INTERMEDIATES OCCURRING THEREIN | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | ALDH1A1 3739/4885KDM4E 2446/4885HPGD 632/4885 |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | ALDH1A1 3014/4885KDM4E 2143/4885HPGD 873/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | ALDH1A1 3739/4885KDM4E 2446/4885HPGD 632/4885 |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | ACE, CYP27A1, LIPC | ALDH1A1 857/4885KDM4E 989/4885HPGD 729/4885 |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | FEN1, RCE1, APEX1 | ALDH1A1 4188/4885KDM4E 1800/4885HPGD 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.